Title: Comparative Real-world Outcomes between Ustekinumab, Infliximab, and Adalimumab
in Bio-naïve and Bio-experienced Crohn’s Disease Patients: A Retrospective Multicenter Study
Version: 3 Date: 24 Apr 2024
Reviewer's report:
Thank you for your hard work.
With careful Revise work, the problems I thought were gone. I hope that in the future, this will
lead to further research and analysis that includes past treatment history and endoscopic severity.
Title: Comparative Real-world Outcomes between Ustekinumab, Infliximab, and Adalimumab
in Bio-naïve and Bio-experienced Crohn’s Disease Patients: A Retrospective Multicenter Study
Version: 3 Date: 24 Apr 2024
Reviewer's report:
Thank you for your hard work.
With careful Revise work, the problems I thought were gone. I hope that in the future, this will
lead to further research and analysis that includes past treatment history and endoscopic severity.
Please review this paper.
user
Title: Comparative Real-world Outcomes between Ustekinumab, Infliximab, and Adalimumab
in Bio-naïve and Bio-experienced Crohn’s Disease Patients: A Retrospective Multicenter Study
Version: 3 Date: 24 Apr 2024
Reviewer's report:
Thank you for your hard work.
With careful Revise work, the problems I thought were gone. I hope that in the future, this will
lead to further research and analysis that includes past treatment history and endoscopic severity.
assistant